Relevance of comorbidities and antithrombotic medication as risk factors for reoperation in patients with chronic subdural hematoma

Alexander Younsi1 · Lennart Riemann1 · Cleo Habel1 · Jessica Fischer1 · Christopher Beynon1 · Andreas W. Unterberg1 · Klaus Zweckberger1

Received: 15 July 2020 / Revised: 14 February 2021 / Accepted: 24 March 2021 / Published online: 9 July 2021 © The Author(s) 2021

Abstract
In an aging Western society, the incidence of chronic subdural hematomas (cSDH) is continuously increasing. In this study, we reviewed our clinical management of cSDH patients and identified predictive factors for the need of reoperation due to residual or recurrent hematomas with a focus on the use of antithrombotic drugs. In total, 623 patients who were treated for cSDH with surgical evacuation between 2006 and 2016 at our department were retrospectively analyzed. Clinical and radiological characteristics and laboratory parameters were investigated as possible predictors of reoperation with univariate and multivariate analyses. Additionally, clinical outcome measures were compared between patients on anticoagulants, on antiplatelets, and without antithrombotic medication. In univariate analyses, patients on anticoagulants and antiplatelets presented significantly more often with comorbidities, were significantly older, and their risk for perioperative complications was significantly increased. Nevertheless, their clinical outcome was comparable to that of patients without antithrombotics. In multivariate analysis, only the presence of comorbidities, but not antithrombotics, was an independent predictor for the need for reoperations. Patients on antithrombotics do not seem to necessarily have a significantly increased risk for residual hematomas or rebleeding requiring reoperation after cSDH evacuation. More precisely, the presence of predisposing comorbidities might be a key independent risk factor for reoperation. Importantly, the clinical outcomes after surgical evacuation of cSDH are comparable between patients on anticoagulants, antiplatelets, and without antithrombotics.

Keywords Chronic subdural hematoma · Antithrombotics · Anticoagulants · Antiplatelets · Comorbidities · Reoperation · Risk factors

Introduction
Chronic subdural hematomas (cSDH) are among the most common neurosurgical conditions that predominately affect elderly patients [14]. Although commonly mild in its early symptoms, cSDH might turn into a severe disease with high recurrence and complication rates reaching 29%, finally resulting in increased mortality [32, 44]. In an aging society of industrialized countries, the incidence of this disease is expected to double in the next 20 years, becoming the most common neurosurgical condition by the year 2030 [6, 14]. This is accompanied by a rising complexity of patients, commonly presenting with underlying chronic diseases and being treated with antithrombotic medication [17].

Despite these upcoming challenges, several aspects of the clinical management of cSDH, predictors for its recurrence, and the role of antithrombotics on recurrence rates and clinical outcome are still unclear. In recent decades, numerous predictors for recurrence have been suggested, including epidemiological characteristics, radiological findings, clinical symptoms, and even laboratory values: Examples of such prognostic factors are higher age, male sex, hypertension, anticoagulants, hyperdense hematoma components or midline shift on preoperative imaging, and also elevated blood urea nitrogen or low levels of high-density lipoprotein. However, the results between various studies have remained conflicting and partly contradictory [13, 26, 31, 33, 34, 44, 46]. Especially the effects of antithrombotics
on the risk of re-hemorrhage and the clinical outcome are widely disputed. Several studies showed an increased risk for cSDH recurrence in patients on antithrombotics, including a recent meta-analysis in which anticoagulants, as well as antiplatelets, were identified as risk factors [13, 33, 47]. Other authors, however, could not find such associations, and in another recent meta-analysis, antiplatelets but not anticoagulants were linked to postoperative cSDH recurrence [3, 15, 34, 38].

In this study, we sought to analyze the characteristics and management of surgically treated cSDH patients on anticoagulants and antiplatelets with respect to clinical outcome and complications. Furthermore, we aimed to identify factors predicting the need for reoperation due to residual hematomas or rebleeding.

Materials and methods

Patients

The medical charts of consecutive adults (18 years or older) treated surgically for cSDH at a single neurosurgical department from 2006 to 2016 were retrospectively analyzed. All cases of acute SDH, acute on chronic SDH, subdural hygroma, or subdural empyema, as well as all patients with prior cranial surgeries, were excluded (Fig. 1). All methods were carried out following relevant guidelines and regulations (Declaration of Helsinki). The standing committee of ethical practice of the Medical Faculty of the University of Heidelberg, Heidelberg, Germany, approved this study’s protocol. It waived the consent from analyzed patients due to its retrospective design.

Treatment characteristics

Patients with cSDH confirmed by head CT were prepared for surgical evacuation if presenting with focal symptoms, deterioration in neurological status, or clinical signs such as headaches, combined with relevant radiologic hematoma appearance. The decision to operate was taken by the consultant neurosurgeon in charge. Patients were subjected to a blood panel that included the coagulation assays, international normalized ratio (INR), activated partial thromboplastin time (aPTT), and a platelet count, and in some cases, the assessment of platelet function. Although there was no unified institutional protocol for anticoagulation reversal, INR values < 1.3 were generally
pursued in patients on antithrombotics for adequate hemostasis. In the case of patients on vitamin K antagonists (VKA), prothrombin complex concentrate (PCC) therapy was considered the first-line treatment, and two different 4-factor PCC products were used depending on their availability (Beriplex P/N® (CSL Behring, Marburg, Germany) and Octaplex® (Octapharma, Langenfeld, Germany)). As a general practice, administration of antithrombotic drugs was stopped on the day of admission if not urgently required due to, e.g., new coronary vessel stents and was resumed 14 days after surgery.

Patients with cSDH were usually treated with burr hole trepanation under intubation anesthesia. If present, inner membranes and/or septations were opened intraoperatively, and subsequent subdural drainage was performed for 48 h in supine position postoperatively as a standard practice. Of note, steroids were not perioperatively administered to any patient. Thromboprophylaxis was carried out using elastic stockings and subcutaneous administration of low molecular weight heparin (Enoxaparin, Clexane®, Sanofi-Aventis, Frankfurt, Germany) once daily (usually 4000 I.U.), starting within 24 h after surgery. CT scans after hematoma evacuation were only performed when the neurological status deteriorated or when preoperative symptoms did not improve. The decision for reoperation was based primarily on clinical findings in combination with CT imaging (e.g., continued or increased midline shift). The second evacuation surgery was performed with a repeat burr hole drainage or a craniotomy, depending on the residual or recurrent hematoma’s extent and consistency.

Outcome variables and end points

The following patient and treatment characteristics were collected: sex, age, cSDH etiology, laboratory values, radiological features on CT imaging, initial Glasgow Coma Scale (GCS), modified Rankin Scale (mRS), first symptom, main symptom, comorbidities, antithrombotics during the last 7 days before admission, surgical procedure, complications (cardiovascular, pulmonary, coagulation, or neurological), clinical course, in-hospital mortality, Glasgow Outcome Scale (GOS), and mRS on discharge. The variable “history of chronic comorbidity” refers to patients having at least one comorbidity (yes/no). The exact duration of the pausing of antithrombotic medication prior to and after the primary operation was not taken into account.

This study’s primary endpoint was the risk of reoperation (due to residual or recurrent hematomas) within 30 days after the first surgical intervention. Secondary endpoints were clinical outcome measures on discharge.

Statistical analysis

Categorical variables were tested with the chi-squared test followed by pairwise post hoc tests with p-value adjustment for multiple testing. The Mann–Whitney U test was used for continuous variables between two and the Kruskal–Wallis test followed by a post hoc Dunn’s test between multiple groups. For the comparative analyses, patients were excluded when being on both anticoagulant and antiplatelet medication. Univariate and multivariate logistic regression regarding reoperation within 30 days with the most plausibly important variables age, gender, comorbidity, antithrombotic medication, and cSDH thickness as predictors was performed. Statistical significance was defined by p-values < 0.05. Results are given, unless stated otherwise, as median ± interquartile range (IQR). All statistical analyses were conducted using the software R (Version 3.5.1) [40].

Results

Patient and treatment demographics

A total of 623 patients (median age: 75 [68–81] years, male/female ratio: 2.24) who underwent surgical cSDH evacuation during the study period were included (Fig. 1). Headaches (28%), coordination deficits (24%), aphasia (11%), and confusion (11%) were the most common initial symptoms that patients reported. The most common leading symptoms at admission were coordination deficits (26%), hemiparesis (15%), aphasia (14%), and reduced vigilance (14%). The prevalence of comorbidities in the cSDH patient population was high (63%), and arterial hypertension, as well as cardiac arrhythmias, accounted for most of them (35% and 21%, respectively). On head CT imaging, cSDH had a median thickness of 21 [15-25] mm, were right-sided in 31%, left-sided in 41%, and bilateral in 28% of cases, while a midline shift was visible in 67% with a median of 6 [2-10] mm. Antithrombotics were present in more than half of all cSDH patients (51%) and were almost equally distributed between only anticoagulant (47%) and only antiplatelet (50%) drugs, with few patients (3%) receiving both. Substances used for anticoagulation were either VKA (89%), new oral anticoaguants (10%), or heparin (1%). Inhibition of platelet function was mostly induced with acetylsalicylic acid (88%) or with clopidogrel (3%) and sometimes with a combination of both drugs (9%).

Management of antithrombotics included assessment of plasmatic coagulation or platelet function, which influenced the timing of surgery: Provided that no urgent indication was present, surgery was delayed for a median of 3 [2-4] days post-admission with the antithrombotics being terminated and the corresponding patients (29%) being clinically...
observed on the normal ward. Moreover, hemostatic therapy was applied in 55% of all such patients before or during surgery. Thereby, PCC (62%), phytonadione (7%; Konakion®, Roche Pharmaceuticals, Grenzach, Germany) or PCC, and phytonadione (19%) and in rare cases, fresh frozen plasma (FFP; 3%), were used for anticoagulants and desmopressin (55%; Minirin®, Ferring Arzneimittel, Kiel, Germany), tranexamic acid (18%; Cylklokapron®, Pfizer, Berlin, Germany), a combination of both drugs (10%), or platelet transfusions (12%) for antiplatelets.

Hematoma evacuation was performed by burr hole drainage in 93% of cases, while the remaining patients received a craniotomy. One or more subdural drains were placed in all patients. During the hospital stay, nine patients (1%) died from inter alia cardiopulmonary insufficiency, multiorgan dysfunction due to sepsis, or acute secondary hemorrhage with trans tentorial herniation. On discharge, 94% of the remaining patients had a GCS score between 13 and 15, and the median GOS and mRS scores were 5 [4-5] and 1 [1-3], respectively. While half of the patients needed secondary hospital or rehabilitation care, the other half could be discharged home. Within 30 days of the primary surgical intervention, the overall reoperation rate due to remaining or recurrent cSDH was 23%.

Reoperation after cSDH recurrence

Reoperation within 30 days of the primary hematoma evacuation was performed in 145 cSDH patients (23%) due to either neurological deterioration or missing improvements caused by residual or recurrent hematomas. A burr hole trepanation was performed in 58% of those cases, while 42% of patients underwent a craniotomy during the second operation.

In the univariate logistic analysis, only the presence of comorbidities in general, as well as arterial hypertension and renal insufficiency as comorbidities, were found to be significant predictors for the need for reoperation within 30 days (Table 1). Moreover, in the multivariate analysis that included age, gender, known comorbidities, antithrombotic medication, and cSDH thickness as covariates, only a history of chronic comorbidity (OR 2.12; 95% CI, 1.30–3.55; \( p = 0.003 \)) was found to be an independent predictor for reoperation as well.

Patients with anticoagulants, antiplatelets, and without antithrombotics

In our study, 151 patients were on anticoagulant and 159 patients were on antiplatelet medication, respectively (Table 2). Compared to patients without antithrombotic medication, those patients were significantly older (\( p < 0.001 \) each) and predominately males (\( p = 0.0432 \) each; Supplement 1).

A mild brain injury (GCS 13–15) was documented in 85% and 88% of patients on anticoagulants and antiplatelets, respectively, vs. in 89% of patients without antithrombotics. A moderate injury (GCS 9–12) was present in 11% (anticoagulant) and 8% (antiplatelet) vs. 6% (no antithrombotic medication) and a severe injury (GCS <9) in 3% (anticoagulant) and 3% (antiplatelet) vs. 4% (no antithrombotic medication).

Known comorbidities were most frequently found in patients on anticoagulants (83%), and thus significantly more common than in patients on antiplatelets (65%; \( p = 0.001 \); Supplement 1). Compared to patients without antithrombotic medication, however, known comorbidities (51%) were found significantly more often in both, the anticoagulants (\( p < 0.001 \)) and the antiplatelets (\( p = 0.010 \)) groups. As expected, cardiac arrhythmias were predominantly found in patients on anticoagulants (60%), while patients on antiplatelets most often suffered from arterial hypertension (42%). Furthermore, anticoagulant and antiplatelet medication were both significantly associated with the comorbidities stroke (\( p = 0.005 \) and \( p = 0.003 \)), diabetes mellitus (\( p = 0.018 \) and \( p < 0.001 \)), and renal insufficiency (\( p = 0.008 \) and \( p = 0.028 \)). Significant inter-group differences could also be observed in the occurrence of cardiovascular and coagulative complications, which were most frequently found in patients on anticoagulants (7% and 5%, respectively), while neurological complications were highest in the antiplatelets group (25%; Table 2). A significantly higher burden of cardiovascular complications was documented in patients on anticoagulants compared to patients without antithrombotic medication (\( p = 0.028 \); Supplement 1).

There were, however, no significant differences regarding inhospital mortality, GOS, mRS, or reoperation risk within 30 days between patients on anticoagulants, on antiplatelets, or without antithrombotic medication.

Discussion

Clinical management of patients with antithrombotics

The incidence rate of chronic subdural hematomas is rising and has been associated with the increasing use of antithrombotics [17, 28]. Patients with cSDH will, therefore very frequently present with antithrombotic medication and chronic comorbidities that need to be considered in their clinical management.

In contrast to other reported strategies, where patients on antiplatelet drugs with cSDH routinely receive platelet transfusions, only a few such patients received a platelet
transfusion before surgery in this study. In recent years, the use of platelet transfusions in emergencies such as intracranial bleedings has been questioned due to reports of lacking benefit or even detrimental effects [2, 9, 20]. In the prospective, multi-center PATCH-study, platelet transfusion was concluded to be inferior to standard care in patients with spontaneous intracerebral hemorrhage. It was associated with higher complication and mortality rates [5]. Our study suggests that cSDH patients on antiplatelet drugs can have an excellent clinical outcome, as measured by GOS, without the extensive use of platelet transfusions. Instead, assessing platelet function and a short delay of the surgical intervention under clinical observation or hemostatic treatment with, e.g., desmopressin or tranexamic acid in more urgent cases seem to be sufficiently effective management strategies. Of note, the addition of tranexamic acid to standard surgical cSDH drainage has been associated with a delay of hematoma recurrence and a reduction of residual hematoma volume in a recent prospective randomized trial, indicating that it might be the preferable choice when hemostatic management of cSDH patients on antiplatelets is required [45].

Anticoagulants such as VKA have traditionally been reversed with FFP. However, delay in hemostasis correction and potential volume overload make FFP not an ideal reversal agent [23]. A rapid hemostasis correction without volume overload can be achieved with PCC. While this compound has been implemented in European guidelines for rapid anticoagulation reversal and has been routinely used in European countries for many years, 4-factor PCC,

| Characteristic | No reoperation | Reoperation | Univariate analysis p-value | Multivariate analysis p-value | Multivariate analysis OR (95% CI) |
|---------------|---------------|-------------|-----------------------------|------------------------------|----------------------------------|
| No. of patients | 478 | 145 | - | - | - |
| Gender | | | | | |
| Male | 328 (69%) | 103 (71%) | 0.581 | 0.504 | 1.18 (0.72–1.90) |
| Female | 150 (31%) | 42 (29%) | | | |
| Median age [IQR] | 75 [68–82] years | 75 [69–80] years | 0.482 | 0.192 | 0.99 (0.97–1.00) |
| Antithrombotics | 234 (44%) | 84 (54%) | 0.059 | 0.163 | 1.20 (0.81–1.77) |
| Anticoagulants | 109 (23%) | 42 (29%) | 0.193 | | |
| Antiplatelets | 117 (24%) | 42 (29%) | 0.384 | | |
| Both | 8 (2%) | 0 (0%) | 0.076 | | |
| Comorbidities | | | | | |
| Known comorbidities | 280 (59%) | 111 (77%) | p<0.001 | 0.003 | 2.12 (1.30–3.55) |
| Arterial hypertension | 152 (32%) | 63 (43%) | | | |
| Cardiac arrhythmias | 90 (19%) | 38 (26%) | 0.055 | | |
| Coronary artery disease | 53 (11%) | 25 (17%) | 0.052 | | |
| Stroke history | 26 (5%) | 9 (6%) | 1.000 | | |
| Diabetes mellitus | 63 (13%) | 24 (17%) | 0.306 | | |
| Malignancy | 41 (9%) | 14 (10%) | 0.689 | | |
| Renal insufficiency | 27 (6%) | 16 (11%) | 0.028 | | |
| Alcohol abuse | 11 (2%) | 4 (3%) | 0.753 | | |
| Median laboratory values [IQR] | | | | | |
| INR | 1.03 [0.87–1.09] | 1.04 [0.88–1.14] | 0.768 | | |
| aPTT (s) | 25.1 [23.3–27.3] | 24.9 [23.4–27.5] | 0.981 | | |
| Platelet count (10⁹/L) | 243 [194–303] | 242 [193–321] | 0.458 | | |
| Creatinine (mg/dL) | 0.84 [0.73–1.02] | 0.85 [0.70–1.07] | 0.219 | | |
| GFR (mL/min/1.73m²) | 81 [66–92] | 79 [63–92] | 0.568 | | |
| Initial clinical presentation | | | | | |
| GCS [IQR] | 15 [14–15] | 14 [14–15] | 0.268 | | |
| mRS [IQR] | 2 [2–3] | 3 [2–3] | 0.095 | | |
| Midline shift | 330 (82%) | 89 (79%) | 0.595 | | |
| Median cSDH thickness [IQR] | 20 [15–25] mm | 22 [16–27] mm | 0.238 | 0.177 | 1.02 (0.99–1.05) |

aPTT, activated partial thromboplastin time; GCS, Glasgow Coma Scale; GFR, glomerular filtration rate; INR, international normalized ratio; IQR, inter quartile range; mRS, modified Rankin scale.
as used in this study, was not approved in the USA until 2013. In our study, most patients with cSDH and anticoagulant medication received PCC prior to surgery (62%). Of note, the rate of complications related to coagulation was significantly increased in patients on anticoagulants in general, underlining that caution might still be warranted when reversing anticoagulation.

Surprisingly, a considerable number of patients (15%) had not received any reversal of their anticoagulants prior to surgery. We attribute this to the fact that reversal of direct Xa-inhibitors with the corresponding drugs or with PCC has been proven to be feasible and effective only recently and had therefore not been performed in this retrospective analysis between 2006 and 2016. Our current management of such cSDH patients, however, includes, depending on the severity of symptoms, admission for observation, and monitoring of drug activity until surgery can be safely performed as well as the urgent reversal of the direct Xa-inhibitors with PCC or specific antagonists if necessary.

**History of chronic disease as an independent predictor for reoperation**

Recurrence of the hematoma requiring surgery is a frequent complication in patients with cSDH. More than 20 factors have been suggested as predictors for cSDH recurrence in several studies, reflecting the difficulty in classifying and predicting this disease’s course [7, 33, 34, 42, 44]. Especially antithrombotics, and more specifically Clopidogrel and Warfarin, are highly debated as risk factors for recurrences [33, 38]. Several authors report results both in favor

| Characteristics                     | No antithrombics | Anticoagulation | Antiplatelet | p-value |
|-------------------------------------|------------------|-----------------|--------------|---------|
| No. of patients                     | 305              | 151             | 159          |         |
| Gender                              |                  |                 |              | <0.006  |
| Male                                | 193 (63%)        | 114 (76%)       | 119 (75%)    |         |
| Female                              | 112 (37%)        | 37 (24%)        | 40 (25%)     |         |
| Median age [IQR]                    | 73 [63–79] years | 77 [71–80] years | 77 [70–84] years | <0.001  |

**Initial clinical presentation**

|                      | No antithrombics | Anticoagulation | Antiplatelet | p-value |
|----------------------|------------------|-----------------|--------------|---------|
| GCS 13–15            | 272 (89%)        | 129 (85%)       | 140 (88%)    | 0.428   |
| GCS 9–12             | 17 (6%)          | 16 (11%)        | 13 (8%)      | 0.150   |
| GCS <9               | 13 (4%)          | 5 (3%)          | 5 (3%)       | 0.788   |
| mRS [IQR]            | 2 [2, 3]         | 3 [2, 3]        | 3 [2, 3]     | 0.164   |

**Comorbidities**

|                      | No antithrombics | Anticoagulation | Antiplatelet | p-value |
|----------------------|------------------|-----------------|--------------|---------|
| Known comorbidities  | 155 (51%)        | 125 (83%)       | 103 (65%)    | <0.001  |
| Arterial hypertension| 79 (26%)         | 66 (44%)        | 66 (42%)     | <0.001  |
| Cardiac arrhythmias  | 21 (7%)          | 90 (60%)        | 11 (7%)      | <0.001  |
| Coronary heart disease| 18 (6%)       | 26 (17%)        | 31 (19%)     | <0.001  |
| Stroke history       | 6 (2%)           | 13 (9%)         | 15 (9%)      | <0.001  |
| Diabetes mellitus    | 25 (8%)          | 26 (17%)        | 35 (16%)     | <0.001  |
| Renal insufficiency  | 10 (3%)          | 17 (11%)        | 15 (9%)      | 0.002   |
| Alcohol abuse        | 11 (4%)          | 3 (2%)          | 1 (1%)       | 0.131   |

**Complications**

|                      | No antithrombics | Anticoagulation | Antiplatelet | p-value |
|----------------------|------------------|-----------------|--------------|---------|
| Complications: cardiovascular | 4 (1%)   | 10 (7%)         | 3 (2%)       | 0.003   |
| Complications: pulmonary         | 11 (4%) | 8 (5%)         | 12 (8%)      | 0.181   |
| Complications: coagulation       | 5 (2%)  | 8 (5%)         | 0 (0%)       | 0.004   |
| Complications: neurological      | 46 (15%) | 35 (23%)       | 39 (25%)     | 0.022   |

**Outcome**

|                      | No antithrombics | Anticoagulation | Antiplatelet | p-value |
|----------------------|------------------|-----------------|--------------|---------|
| In-hospital mortality| 5 (2%)           | 1 (1%)          | 3 (2%)       | 0.628   |
| GOS at discharge [IQR]| 5 [5–5]       | 5 [4–5]         | 5 [4–5]      | 0.595   |
| mRS at discharge [IQR]| 1 [1–3]        | 2 [1–3]         | 2 [1–3]      | 0.262   |
| Reoperation < 30 days   | 61 (20%)        | 42 (28%)        | 42 (26%)     | 0.112   |

**Table 2 Characteristics, clinical course, and outcome in cSDH patients with anticoagulant, antiplatelet, and no antithrombotic medication**

aPTT, activated partial thromboplastin time; GCS, Glasgow Coma Scale; GFR, glomerular filtration rate; GOS, Glasgow Outcome Scale; INR, international normalized ratio; mRS, modified Rankin scale
and against this notion, and final conclusions cannot be drawn [3, 15, 33–35, 39, 44]. In this study, we found no link between antithrombotics and an increased reoperation risk due to residual or recurrent hematomas within 30 days after surgery in the univariate or multivariate analysis. Moreover, despite our data showing that a larger proportion of patients with either anticoagulants or antiplatelets underwent a reoperation than patients with no antithrombotics, these differences did not reach statistical significance. Instead, the prevalence of chronic diseases in the patient history was identified as an independent predictor for reoperation (Fig. 2). Therefore, the fact that patients under antithrombotics had more rebleeding might not be explained by the antithrombotics themselves but by the presence of the underlying chronic diseases.

Group comparisons between the patients with anticoagulant vs. antiplatelet vs. no antithrombotic medication showed several distinctive and significant differences: Patients on either anticoagulants or antiplatelets were generally older and presented more commonly with chronic comorbidities (Fig. 3). Systemic, chronic diseases are known to predispose to vascular complications and increased bleeding tendency. Arterial hypertension, for example, is a known risk factor for post-craniotomy intracranial hemorrhage, and diabetes mellitus is reported to increase the risk for intracranial hemorrhages [8, 11]. An increased bleeding tendency due to, among others, platelet dysfunction has also been shown in patients with renal insufficiency, and an association has been made between coronary heart disease and traumatic intracranial hemorrhages in a large, population-based study, with atherosclerotic vessel changes as a likely shared underlying pathology [25, 27]. In our study, the prevalence of arterial hypertension and renal insufficiency was significantly higher in the patient group with revision surgery. Results similar to ours have been reported in several other studies, with chronic diseases such as hypertension and diabetes mellitus being independent risk factors for hematoma recurrence [37, 42, 44]. A history of stroke has also been identified as an independent predictor for cSHD recurrence in a study by Okano et. al [36].
It is, therefore, important for clinicians to consider chronic comorbidities in patients when evaluating the risk for hematoma recurrence. Moreover, given the increased interest in minimally invasive procedures for the treatment of cSDH, such as embolization of the middle meningeal artery, which claim to reduce the recurrence rates compared to cSDH surgery, an emphasis on chronic comorbidities, as proposed by our data, might be relevant for the design of future, prospective studies [18].

While not the focus of the current study, the association of peri-operative steroid use (which was not part of our treatment regimen for cSDH) with the necessity of repeat operations has been the focus of recent investigations and is currently under critical discussion: Several reports on beneficial effects of steroids on cSDH recurrence exist, but some authors also observed contradictory and even adverse effects [12, 19, 24, 48]. Correspondingly, the very recently published multicenter, randomized DEX-CSDH trial has reported fewer repeat operations but at the same time also fewer favorable outcomes and more adverse events with a 2-week oral dexamethasone treatment compared to placebo at 6 months [21]. Although more prospective studies are currently underway, especially in more vulnerable patients with chronic comorbidities, the peri-operative administration of steroids should thus be evaluated with caution [29, 30].

**Clinical outcome is not worsened by the use of antithrombotics**

While a vast number of authors have tried to investigate the association between antithrombotics and hematoma recurrence rates in cSDH patients, only a few studies have examined the impact of antithrombotics on the clinical outcome itself. Those few studies have shown very different results, ranging from anticoagulants as negative predictors for good outcome, neither anticoagulants nor antiplatelets as predictive factors for poor outcome, to antiplatelets as even a predictor for a good outcome [1, 22, 41].

This study examined the clinical outcome (GOS, mRS) of 151 cSDH patients on anticoagulants and 159 cSDH patients on antiplatelets after surgical hematoma removal and compared findings to a cohort of cSDH patients without such antithrombotic medication. The in-hospital mortality rate was 1% for anticoagulants, 2% for antiplatelets, and 2% for no-antithrombotics (no significant difference). In our study, antithrombotics were thus not linked to higher mortality in cSDH patients, which is in line with similar findings by Fornebo et al. [15]. The median GOS at discharge was 5 in all groups. However, the median mRS was lower in the no-antithrombotics group (1) compared to the anticoagulants and antiplatelets group (both 2), without reaching a significant difference. Similarly, in the multicenter prospective cohort study by Poon et al., neither antiplatelet nor anticoagulant drug use was associated with worse clinical outcomes after cSDH surgery [39]. However, in a recent study by Atsumi et al. [4], comorbidities such as hemodialysis and chronic heart failure were linked to the impairment of activities of daily living in patients with cSDH, while similar to our findings, antithrombotics themselves were no independent risk factor. Taken together, these data may indicate that neither anticoagulants nor antiplatelets necessarily lead to a worse clinical outcome in surgically treated cSDH patients if managed adequately.

Our findings, therefore, may support the notion that surgical intervention for cSDH is highly indicated even in patients on antithrombotics, as their chances for a good clinical outcome (GOS 5) can be considered very good.

**Limitations**

Further studies are needed to determine optimal protocols for the reversal of anticoagulants and antiplatelets and, more importantly, for the clinical management of patients with chronic comorbidities and a high risk for recurrent bleedings, as this study comes with several limitations: Due to its retrospective design, it might be subject to selection and information biases albeit its large cohort of 623 patients. While the surgical, as well as the clinical management of cSDH patients, has remained unchanged during the 10-year course of the study, including, e.g., the strict peri-operative avoidance of steroids, management of antithrombotics might have varied. A prospective study is needed to minimize those biases. Although we aimed to exclude acute on chronic subdural hematomas in this analysis, the lack of a uniform definition of this entity might be a further bias, limiting the generalization of the results [10]. Also, we did not further investigate the association of each type of antithrombotic agent (e.g., DOAKs) to reoperation, as subgroups were too small for statistical analysis. Another limitation might be our clinical practice to limit postoperative CT scans to patients without improvement of preoperative symptoms or neurological deterioration, which, in the absence of routine follow-up CT scans, makes it difficult to differentiate between residual or recurrent bleedings in cases of revision surgery. Recent data has, however, supported this practice, showing no impact on patient management of routine follow-up CT [16] and even suggesting a correlation with increased rate of revision surgeries [43]. Finally, limitations due to the assessment of cSDH reoperations within only 30 days after the primary surgery have to be noted. Potential hematoma recurrences at later timepoints were thus not considered and additional studies with longer follow-up periods are warranted.
Conclusion

In conclusion, our current data show that patients on antithrombotics have no significantly higher risk of reoperation due to residual hematomas or rebleeding compared to patients without antithrombotics in multivariate analysis (Fig. 4). However, a history of chronic diseases was identified as an independent predictive factor for the need for reoperation within 30 days after initial hematoma evacuation. An increased recurrence rate in patients on antithrombotics might thus not be explained by the medication itself but by the presence of chronic comorbidities such as hypertension and renal insufficiency, which are distinctively more common in such patients and might predispose to rebleeding. Neither the mortality rate nor the clinical outcome was worse in patients on anticoagulants or antiplatelets after evacuation surgery than patients without antithrombotics.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10143-021-01537-x.

Acknowledgements We thank Julia Mattern and Madlen Rädel for their help with this study.

Author contribution AY, CB, AU, and KZ designed the study. AY, CH, JF, and LR collected the data. AY and LR analyzed the data. AY and LR equally wrote the main manuscript text and prepared all figures and tables. All authors reviewed the manuscript.

Funding Open Access funding enabled and organized by Projekt DEAL.

Data availability The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Code availability Not applicable.

Declarations

Ethics approval The standing committee of ethical practice of the Medical Faculty of the University of Heidelberg, Heidelberg, Germany, approved this study’s protocol.

 Consent to participate Consent to participate was waived by the standing committee of ethical practice of the Medical Faculty of the University of Heidelberg, Heidelberg, Germany, due to this study’s retrospective design.

Consent for publication Not applicable.

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Abboud T, Dührsen L, Gibbert C, Westphal M, Martens T (2018) Influence of antithrombotic agents on recurrence rate and clinical outcome in patients operated for chronic subdural hematoma. Neurosurgery 29:86–92. https://doi.org/10.1016/J.NEUCIR.2017.09.006

2. Al-Shahi Salman R, Law ZK, Bath PM, Steiner T, Sprigg N (2018) Haemostatic therapies for acute spontaneous intracerebral haemorrhage. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD005951.pub4

3. Aspegren OP, Astrand R, Lundgren MJ, Romner B (2013) Anticoagulation therapy as a risk factor for the development of chronic subdural hematoma. Clin Neurol Neurosurg 115:981–984. https://doi.org/10.1016/J.CLLINEURO.2012.10.008

4. Atsumi H, Sorimachi T, Honda Y, Sunaga A, Matsumae M (2019) Effects of pre-existing comorbidities on outcomes in patients with chronic subdural hematoma. World Neurosurg 122:e924–e932. https://doi.org/10.1016/j.wneu.2018.10.176

5. Baharoglu MI, Cordonnier C, Al-Shahi Salman R, de Gans K, Koopman MM, Brand A, Majoie CB, Beenen LF, Marquering HA, Vermeulen M, Nederkoorn PJ, de Haan RJ, Roos YB, Investigators PATCH (2016) Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet (London, England) 387:2605–2613. https://doi.org/10.1016/S0140-6736(16)30392-0
6. Balser D, Farooq S, Mehmod T, Reyes M, Samadani U (2015) Actual and projected incidence rates for chronic subdural hematoma in United States Veterans Administration and civilian populations. J Neurosurg 123:1209–1215. https://doi.org/10.3171/2014.9.JNS141550

7. Bartek J, Sjävik K, Kristiansson H, Ståhl F, Fornebo I, Förndér P, Jakola AS (2017) Predictors of recurrence and complications after chronic subdural hematoma surgery: a population-based study. World Neurosurg 106:609–614. https://doi.org/10.1016/j.wneu.2017.07.044

8. Basali A, Mascha EJ, Kalfias I, Schubert A (2000) Relation between perioperative hypertension and intracranial hemorrhage after craniotomy. Anesthesiology 93:48–54

9. Batchelor JS, Grayson A (2012) A meta-analysis to determine the effect on survival of platelet transfusions in patients with either spontaneous or traumatic antplatelet medication-associated intracranial haemorrhage. BMJ Open 2:e000588. https://doi.org/10.1136/bmjopen-2011-000588

10. Beynon C, Brenner S, Younsi A, Rizos T, Neumann J-O, Pfaff J, Unterberg AW (2019) Management of patients with acute subdural hemorrhage during treatment with direct oral anticoagulants. Neurocrit Care 30:322–333. https://doi.org/10.1007/s12028-018-0635-4

11. Boulanger M, Poon MTC, Wild SH, Al-Shahi Salman R (2016) Association between diabetes mellitus and the occurrence and outcome of intracerebral hemorrhage. Neurology 87:870–878. https://doi.org/10.1212/WNL.000000000003021

12. Cardim D, Cossyka M, Chandrapathum K, Badenes R, Bertuccio A, DI NA, Donnelly J, Pelosi P, Bull L, Hutchinson PJ, Robba C (2020) Effects of age and sex on optic nerve sheath diameter in healthy volunteers and patients with traumatic brain injury. Front Neurol 11:1–9. https://doi.org/10.3389/fneur.2020.00764

13. Chon K-H, Lee J-M, Koh E-J, Choi H-Y (2012) Independent predictors for recurrence of chronic subdural hematoma. Acta Neurochir (Wien) 154:1541–1548. https://doi.org/10.1007/s00701-012-1399-9

14. Ducruet AF, Grobelny BT, Zacharia BE, Hickman ZL, DeRosa PL, Anderson K, Sussman E, Carpenter A, Connolly ES (2012) The surgical management of chronic subdural hematoma. Neurosurg Rev 35:155–169. https://doi.org/10.1007/s10143-011-0349-y

15. Fornebo I, Sjävik K, Alikeb M, Kristiansson H, Ståhl F, Förndér P, Jakola AS, Bartek J (2017) Role of anti-thrombotic therapy in the risk of hematoma recurrence and thromboembolism after chronic subdural hematoma evacuation: a population-based consecutive cohort study. Acta Neurochir (Wien) 159. https://doi.org/10.1007/s00701-017-3330-x

16. Frechon P, Emery E, Gaberel T (2020) Is there an interest in performing a systematic CT scan within the first two months after chronic subdural hematoma evacuation? A ten-year single-center retrospective study. Clin Neuroradiol 191:105682. https://doi.org/10.1016/j.clineuro.2020.105682

17. Gaist D, García Rodríguez LA, Hellfritzsch M, Poulsen FR, Halle B, Hallas J, Pottgård A (2017) Association of anti-thrombotic drug use with subdural hematoma risk. JAMA 317:836. https://doi.org/10.1001/jama.2017.0639

18. Haldrup M, Ketharanathan B, Debrabant B, Schwartz OS, Mikelsen R, Fugelholm K, Poulsen FR, Jensen TS, Thaarup LV, Bergholt B (2020) Embolization of the middle meningeal artery in patients with chronic subdural hematoma—a systematic review and meta-analysis. Acta Neurochir (Wien) 162:777–784. https://doi.org/10.1007/s00701-020-04266-0

19. Holl DC, Volovic V, Dirven CMF, van Kooten F, Miah IP, Jellem A, Peul WC, van der Gaag NA, Kho KH, den Hertog HM, Dammers R, Lingmsa HF (2019) Corticosteroid treatment compared with surgery in chronic subdural hematoma: a systematic review and meta-analysis. Acta Neurochir (Wien) 161:1231–1242. https://doi.org/10.1007/s00701-019-03881-w

20. Holzmecher JL, Reynolds C, Patel M, Maluso P, Holland S, Gamsky N, Moore H, Acquista E, Carrick M, Amdur R, Hancock C, Metzler M, Dunn J, Sarani B (2018) Platelet transfusion does not improve outcomes in patients with brain injury on antiplatelet therapy. Brain Inj 32:325–330. https://doi.org/10.1080/02699538.2018.1425804

21. Hutchinson PJ, Edm man E, Bulters D, Zolinourian A, Holton P, Suttner N, Agyemang K, Thomson S, Anderson IA, Al-Tamimi YZ, Henderson D, Whitfield PC, Gherle M, Brennan PM, Allison A, Thelin EP, Tarantino S, Panteleo B, Caldwell K, Davis-Wilkie C, Mee H, W arburton EA, Barton G, Chari A, Marcus H, King AT, Belli A, Myint PK, Wilson K, Santarius T, Turner C, Bond S, Kolas AG (2020) Trial of dexamethasone for chronic subdural hematoma. N Engl J Med 383:2616–2627. https://doi.org/10.1056/nejmoa200473

22. Kuhn EN, Erwood MS, Oster RA, Davis MC, Zeiger HE, Pittman BC, Fisher WS (2018) Outcomes of subdural hematoma in the elderly (SHE) with a history of minor or no prior trauma. World Neurosurg. https://doi.org/10.1016/j.wneu.2018.07.168

23. Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blätt PM (2006) Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 4:967–970. https://doi.org/10.1111/j.1538-7836.2006.01815.x

24. Liebeschkind DS, Marcinkevičius E, Pranevičius M, Pranevičius O (2013) Clinical assessment of noninvasive intracranial pressure absolute value measurement method. Neurology 80:507. https://doi.org/10.1212/WNL.0b013e318281bf4a

25. Lin W-S, Lin C-S, Liou J-T, Lin W-Y, Lin C-L, Cheng S-M, Lin I-C, Kao C-H (2015) Risk of coronary artery disease in patients with traumatic intracranial hemorrhage a nationwide, population-based cohort study. Medicine (Baltimore) 94:e2284. https://doi.org/10.1097/MD.0000000000022884

26. Liu WC, Lin QQ, Jin J, Wang M, You WD, Gu J, Pan JW (2020) An association of low high-density lipoprotein levels with recurrence of chronic subdural hematoma. Acta Neurochir (Wien). https://doi.org/10.1007/s00701-020-04638-6

27. Lutz J, Menke J, Sollinger D, Schinzel H, Thürmel K (2014) Haemostasis in chronic kidney disease. Nephrol Dial Transplant 29:29–40. https://doi.org/10.1093/ndt/gft209

28. Madsen CM, Jantzen C, Lauritzen JB, Abrahamsen B, Jorgensen HL (2016) Temporal trends in the use of anti-thrombotics at admission. Acta Orthop 87:368–373. https://doi.org/10.1080/17435674.2016.1195662

29. Meb berson K, Colditz M, Marshman LAG, Thomas PAW, Mitchell PS, Robertson K (2020) Prospective randomized placebo-controlled double-blind clinical study of adjuvant dexamethasone with surgery for chronic subdural haematoma with post-operative subdural drainage: interim analysis. J Clin Neurosci 71:153–157. https://doi.org/10.1016/j.jocn.2019.08.095

30. Miah IP, Holl DC, Peul WC, Walchenbach R, Kruyt N, De Laat K, Koot RW, Volovic V, Dirven CMF, Van Kooten F, Kho KH, Den Hertog HM, Van Der Naal J, Jacobs B, Groen RJM, Lingmsa HF, Dammers R, Jellem A, Van Der Gaag NA (2018) Dexamethasone therapy versus surgery for chronic subdural haematoma (DECSA trial): study protocol for a randomised controlled trial 11 Medical and Health Sciences 1103 Clinical Sciences. Trials 19:1–10. https://doi.org/10.1186/s13063-018-2945-4

31. Miah IP, Tank Y, Rosendaal FR, Peul WC, Dammers R, Lingmsa HF, den Hertog HM, Jellem A, van der Gaag NA, Dutch Chronic Subdural Hematoma Research Group (2020) Radiological prognostic factors of chronic subdural hematoma recurrence: a systematic review and meta-analysis. Neurocritical Care. https://doi.org/10.1007/s12028-020-02558-x
32. Miranda LB, Braxton E, Hobbs J, Quigley MR (2011) Chronic subdural hematoma in the elderly: not a benign disease. J Neurosurg 114:72–76. https://doi.org/10.1017/JNS10298
33. Motiei-Langroudi R, Steppler M, Shi S, Adeeb N, Gupta R, Griesenauer CJ, Papavassiliou E, Kasper EM, Arle J, Alterman RL, Ogilvy CS, Thomas AJ (2018) Factors predicting reoperation of chronic subdural hematoma following primary surgical evacuation. J Neurosurg 129:1143–1150. https://doi.org/10.3171/2017.6. JNS17130
34. Motioie R, Karashima S, Otsuji R, Ren N, Nagaoka S, Maeda K, Ikai Y, Uno J, Gi H (2018) Recurrence in 787 patients with chronic subdural hematoma: retrospective cohort investigation of associated factors including direct oral anticoagulant use. World Neurosurg 118:e87–e91. https://doi.org/10.1016/j.wneu.2018.06.124
35. Nathan S, Goodarzi Z, Jette N, Gallagher C, Holroyd-Leduc J (2017) Anticoagulant and antiplatelet use in seniors with chronic subdural hematoma: Systematic review. Neurology 88:1889–1893. https://doi.org/10.1212/WNL.0000000000003918
36. Okano A, Oya S, Fujisawa N, Tsujiya T, Indo M, Nakamura T, Chang HS, Matsui T (2014) Analysis of risk factors for chronic subdural haematoma recurrence after burr hole surgery: optimal management of patients on antiplatelet therapy. Br J Neurosurg 28:204–208. https://doi.org/10.3109/02688697.2013.829563
37. Pang CH, Lee SE, Kim CHCH, Kim JEJW, Kang H-S, Park C-K, Paek SH, Kim CHCH, Jahng T-A, Kim JEJW, Kim YH, Kim DG, Chung CK, Jung H-W, Yoo H (2015) Acute intracranial bleeding and recurrence after burr hole craniostomy for chronic subdural hematoma. J Neurosurg 123:65–74
38. Poon MTC, Al-Shahi Salman R (2018) Association between antithrombotic drug use before chronic subdural haematoma and outcome after drainage: a systematic review and meta-analysis. Neurosurg Rev 41:439–445. https://doi.org/10.1007/s10143-017-0860-x
39. Poon MTC, Rea C, Kollas AG, Brennan PM, British Neurosurgical Trainee Research Collaborative (BNTRC) (2019) Influence of antiplatelet and anticoagulant drug use on outcomes after chronic subdural hematoma drainage. J Neurotrauma 8:1–8. https://doi.org/10.1089/neu.2018.6080
40. R Core Team (2018) R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing
41. Scerrati A, Mangiola A, Rigoni F, Olei S, Santantonio M, Trevisi G, Anile C, Cavallo MA, De Bonis P (2018) Do antiplatelet and anticoagulant drugs modify outcome of patients treated for chronic subdural hematoma? Still a controversial issue. J Neurosurg Sci. https://doi.org/10.23736/S0390-5616.18.04311-4
42. Schmidt L, Gertz S, Wohlfahrt J, Melbye M, Munch TN (2015) Recurrence of subdural haematoma in a population-based cohort – risks and predictive factors. PLoS ONE 10:e0140450. https://doi.org/10.1371/journal.pone.0140450
43. Schucht P, Fischer U, Fung C, Bernasconi C, Fichtner J, Vulcu S, Schönig D, Nowacki A, Wanderer S, Eisenring C, Krähenbühl AK, Mattle HP, Arnold M, Söll N, Tochtermann L, Z’Graggen W, Jünger ST, Grailla J, Mordasini P, Dahlweid FM, Raabe ABJ (2019) Follow-up computed tomography after evacuation of chronic subdural hematoma. N Engl J Med 380:1186–1187. https://doi.org/10.1056/NEJMc1812507
44. Schwarz F, Loos F, Dünisch P, Sakr Y, Al SD, Kalf R, Ewald C (2015) Risk factors for reoperation after initial burr hole trephination in chronic subdural hematomas. Clin Neurol Neurosurg 138:66–71
45. Wan KR, Qiu L, Saffari SE, Khong WXL, Ong JCL, See AA, Ng WH, King NKK (2020) An open label randomized trial to assess the efficacy of tranexamic acid in reducing post-operative recurrence of chronic subdural haemorrhage. J Clin Neurosci 82:147–154. https://doi.org/10.1016/j.jocn.2020.10.053
46. Wang N, Hu J, Oppong-Gyebi A, Zhu X, Li Y, Yang J, Ruan L, Zhuge Q, Ye S (2020) Elevated blood urea nitrogen is associated with recurrence of post-operative chronic subdural hematoma. BMC Neurol 20:1–10. https://doi.org/10.1186/s12883-020-01985-w
47. Wang Y, Zhou J, Fan C, Wang D, Jiao F, Liu B, Zhang Q (2016) Influence of antithrombotic agents on the recurrence of chronic subdural hematomas and the quest about the recommencement of antithrombotic agents: A meta-analysis. J Clin Neurosci. https://doi.org/10.1016/j.jocn.2016.12.001
48. Zweckberger K, Liu Y, Wang J, Forgione N, Fehlings MG (2015) Synergetic use of neural precursor cells and self-assembling peptides in experimental cervical spinal cord injury. J Vis Exp e52105. https://doi.org/10.3791/52105

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.